T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas
- 15 September 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 95 (11) , e1582-e1589
Abstract
Objective To assess the predictive value of T2 appearance as a defining criterion of T2–fluid-attenuated inversion recovery (FLAIR) mismatch sign (T2FM), further characterize tumors that display the marker, and describe its radiographic evolution. Methods Records from 64 patients with astrocytomas were assessed for age at diagnosis, sex, tumor characteristics on pretreatment CT, MRI, and pathology, documentation of T2FM, treatment course, and temporal changes in tumor appearance. Cases were divided into those meeting classic criteria (homogenous T2, hyperintense FLAIR rim), those considered geographic (heterogeneous T2, hyperintense FLAIR rim), and those that were negative (no FLAIR rim). Groups were compared using χ2, estimate of effect, and qualitative analyses. Results Including geographic tumors increased T2FM sensitivity 30% among astrocytomas without decreased specificity for IDH mutation. Tumors with T2FM characteristics were more cystic, less enhancing, and affected younger patients. T2FM persisted in residual tumors following subtotal resection and disappeared with radiotherapy, persisted in 5/8 recurrent tumors that were originally T2FM-positive, and was identified in tumors with high-grade characteristics. T2FM was able to predict IDH mutation status on sequencing when antibody testing was negative. Conclusions The presence of a hyperintense FLAIR rim, regardless of T2 appearance, is a reliable indicator of IDH mutation among astrocytomas. Tumors with a FLAIR rim are more cystic and this may lend to their characteristic appearance on MRI. T2FM demonstrates distinctive temporal radiographic changes, may be seen in high-grade gliomas, and may be used in combination with other variables to strengthen prediction of IDH status.Keywords
This publication has 9 references indexed in Scilit:
- Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groupsJournal of Neuro-Oncology, 2018
- The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation studyNeuro-Oncology, 2018
- MRI Features Can Predict 1p/19q Status in Intracranial GliomasAmerican Journal of Neuroradiology, 2018
- T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA ProjectClinical Cancer Research, 2017
- Insular primary glioblastomas with IDH mutations: Clinical and biological specificitiesNeuropathology, 2017
- Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletionJournal of Neuro-Oncology, 2016
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade GliomasNew England Journal of Medicine, 2015
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent GliomaScience, 2014
- IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resectionNeuro-Oncology, 2013